Investigation Launched into Capricor Therapeutics Following Significant Stock Plunge

Capricor Therapeutics Stock Crash and Investor Alert

On July 30, 2026, Hagens Berman, a nationwide law firm advocating for investor rights, announced an investigation into Capricor Therapeutics, Inc. (NASDAQ: CAPR). This probe follows a significant decline in the company's stock price due to allegations of misleading statements regarding the efficacy of its leading product, Deramiocel, aimed at treating Duchenne muscular dystrophy (DMD).

Background of the Stock Decline

The stock price of Capricor Therapeutics dropped drastically by approximately 64% on July 27, 2026, after the release of a critical FDA briefing document. The document was issued ahead of a meeting that was to discuss the resubmission of Capricor's biologics license application for Deramiocel. The information presented by the FDA pointed out that Capricor's Phase 3 clinical trial results did not meet the expected primary and secondary efficacy endpoints—a stark contrast to the company's earlier claims of success.

On December 3, 2025, Capricor had announced "Positive Topline Results from Pivotal Phase 3 HOPE-3 Study of Deramiocel in Duchenne Muscular Dystrophy."
This announcement had led to a surge in Capricor's stock, increasing it by 370% in one day as investors reacted positively to the purported findings. However, the subsequent revelations from the FDA indicated significant discrepancies in how the trial's outcomes were communicated by Capricor.

Key Developments in the Investigation

The firm is looking into whether Capricor adequately disclosed modifications made to its statistical analysis plan (SAP) that govern the clinical trial data analysis. Notably, the FDA's briefing suggested that the study did not demonstrate a statistically significant difference between Deramiocel and a placebo at 12 months, calling into question the validity of Capricor's earlier representations. Furthermore, the FDA reported that changes to the SAP resulted in at least two additional versions, leading to modifications in key endpoint definitions and analytical methods.

Reed Kathrein, a leading partner at Hagens Berman handling this investigation, emphasized the importance of transparency regarding these disclosures and how they may affect the company's license application. Interested investors, especially those who faced substantial losses after the stock decline, are encouraged to speak with the firm.

Protective Measure for Investors

Hagens Berman is actively seeking input from affected investors and whistleblowers with relevant non-public information regarding Capricor's disclosures. The firm highlights that whistleblowers may take part in the SEC Whistleblower program, potentially receiving rewards for providing original information that leads to successful recovery.

The investigation is still in its preliminary stages, but it highlights the critical need for companies to maintain clear and accurate communication with their investors, especially regarding clinical trials and product efficacy. For further assistance, interested investors can reach out to Hagens Berman via their website or hotline for additional information.